SCHEMBL16185127

SCHEMBL16185127

CCOc1cc(-c2ccccc2F)cc2c(NC)nc(-c3ncccn3)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ ALDH1A1 P00352 6/20 0.37
▸ LMNA P02545 4/20 0.37
▸ CYP1A2 P05177 3/20 0.37
▸ CYP3A4 P08684 3/20 0.37
▸ CYP2D6 P10635 3/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ IKBKB O14920 1/20 0.35
▸ CHUK O15111 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ S1PR1 P21453 2/20 0.34
▸ TUBB4A P04350 1/20 0.34
▸ TUBB P07437 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474679 0.92 KLKB1 (0.37) KDM4EHSD17B10SMN1; SMN2HPGDNPSR1
SCHEMBL14475260 0.91 GRM5 (0.42) KDM4EHSD17B10SMN1; SMN2ALDH1A1LMNA
SCHEMBL16185158 0.90 CHRNA7 (0.38) KDM4EHSD17B10SMN1; SMN2HPGDNPSR1
SCHEMBL14474690 0.90 CHRNA7 (0.38) KDM4EHSD17B10SMN1; SMN2HPGDNPSR1
SCHEMBL16185124 0.89 CYP1A2 (0.46) KDM4EHSD17B10SMN1; SMN2HPGDALDH1A1
SCHEMBL16185128 0.88 GRM5 (0.41) KDM4EHSD17B10SMN1; SMN2HPGDNPSR1
SCHEMBL14475261 0.87 S1PR1 (0.41) KDM4EHSD17B10SMN1; SMN2HPGDNPSR1
SCHEMBL16184850 0.87 HSD17B10 (0.47) KDM4EHSD17B10HPGDNPSR1ALDH1A1
SCHEMBL14475257 0.86 GRM5 (0.35) KDM4EHSD17B10SMN1; SMN2HPGDNPSR1
SCHEMBL14475264 0.86 PIM1 (0.36) KDM4EHSD17B10SMN1; SMN2HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB KDM4E 1395/4885HSD17B10 2670/4885SMN1; SMN2 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback